Key result
VerifyNow-guided DAPT de-escalation targets an absolute ~8% reduction in 1-year NACE after ACS.
Why the study?
De-escalation from prasugrel or ticagrelor to clopidogrel after PCI for ACS aims to reduce bleeding, and whether VerifyNow-guided de-escalation based on platelet aggregation measurement provides a therapeutic benefit is being evaluated.
Does VerifyNow-guided de-escalation from ticagrelor or prasugrel to clopidogrel reduce net adverse cardiovascular events (cardiac death, nonfatal myocardial infarction, nonfatal stroke, and BARC >= 2 bleeding) compared to continued ticagrelor or prasugrel in ACS patients post-PCI with very low platelet reactivity (PRU <= 30) at 1 month?
RCT (n=634)
1:1 electronic randomization
Yes
Does VerifyNow-guided de-escalation from ticagrelor or prasugrel to clopidogrel reduce net adverse cardiovascular events (cardiac death, nonfatal myocardial infarction, nonfatal stroke, and BARC >= 2 bleeding) compared to continued ticagrelor or prasugrel in ACS patients post-PCI with very low platelet reactivity (PRU <= 30) at 1 month?
Answers are grounded in this paper and cite their sources.
This study design paper outlines the ongoing EPIC17-VERONICA trial, which is the first randomized trial to evaluate whether using the VerifyNow platelet aggregation test to selectively de-escalate DAPT to clopidogrel in ACS patients with very low platelet reactivity (PRU <= 30) at 1 month improves 1-year net clinical outcomes.
Introduction and objectives: De-escalation from prasugrel and ticagrelor to clopidogrel in patients undergoing percutaneous coronary intervention after acute coronary syndrome (ACS) is a strategy aimed at reducing bleeding. This study evaluates whether VerifyNow (Werfen, Spain)-guided de-escalation, based on platelet aggregation measurement, provides a therapeutic benefit in ACS management. Methods: This ongoing multicenter, prospective, randomized 1:1 trial will enroll 634 patients with ACS who underwent revascularization with a sirolimus-eluting stent and were discharged on dual antiplatelet therapy with ticagrelor or prasugrel. Only those patients with a very low platelet reactivity level (platelet reactivity units ≤ 30) based on VerifyNow 1 month after discharge will be included. The primary endpoint is a composite of cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, and bleeding at 1-year follow-up. Results: The EPIC17-VERONICA study (NCT04654052) will reveal the efficacy profile of the de-escalation strategy, based on the VerifyNow platelet aggregation test, and determine the role of this device in the selection of patients who are eligible to benefit from this strategy. Conclusions: This study will determine whether platelet function testing provide clinical benefit in the management of patients with ACS.
No takes yet. Share an insight, caveat, or question.
Cámara et al. (2025) conducted an RCT in Acute coronary syndrome undergoing percutaneous coronary intervention with very low platelet reactivity (PRU ≤ 30) (n=634). VerifyNow-guided de-escalation to clopidogrel (with acetylsalicylic acid) vs. Continued standard dual antiplatelet therapy with acetylsalicylic acid and ticagrelor or prasugrel was evaluated on Net adverse cardiovascular events (composite of cardiac death, nonfatal myocardial infarction, nonfatal stroke, and BARC grade ≥ 2 bleeding) at 1-year follow-up. VerifyNow-guided de-escalation to clopidogrel is being evaluated in 634 ACS patients with PRU ≤ 30 to detect a projected reduction in 1-year net adverse cardiovascular events from 22% to 14%.
Synapse has enriched 10 related papers. Consider them for comparative context: